Can Atomoxetine Be Taken with Divalproex?
Yes, atomoxetine can be safely co-administered with divalproex (valproic acid), as there are no documented pharmacokinetic interactions or contraindications between these medications.
Drug Interaction Profile
The FDA label for atomoxetine provides comprehensive drug interaction data and does not list valproic acid or divalproex as an interacting medication 1. Atomoxetine is primarily metabolized through the CYP2D6 pathway, while valproic acid does not significantly affect this enzyme system 1.
Key pharmacokinetic considerations:
- Atomoxetine does not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9 1
- Atomoxetine did not affect the binding of other highly protein-bound drugs (warfarin, phenytoin, diazepam) to human albumin 1
- No dose adjustment is required when combining these medications from a pharmacokinetic standpoint
Clinical Context and Monitoring
While the combination is pharmacologically safe, clinical vigilance is warranted:
Monitor for ADHD symptom changes: Recent evidence suggests valproic acid may paradoxically worsen ADHD symptoms. A 2024 prospective study found statistically significant increases in ADHD symptom severity in children treated with valproic acid, with ADHD subscale scores rising post-treatment (p = 0.034) 2. This means you may need higher atomoxetine doses or the atomoxetine may appear less effective—not due to interaction, but due to valproic acid's independent effect on ADHD symptoms.
Cardiovascular monitoring: Both medications require routine monitoring of blood pressure and heart rate 1. Atomoxetine should be used cautiously with any drugs that affect blood pressure 1, though valproic acid is not specifically flagged as problematic in this regard.
Common clinical scenario: This combination is frequently used when treating patients with comorbid epilepsy or bipolar disorder and ADHD. Atomoxetine is particularly useful in these populations as it's a non-stimulant with lower abuse potential 3.
Practical Implementation
Starting the combination:
- No cross-tapering required
- Can initiate atomoxetine while patient is stable on valproic acid
- Standard atomoxetine titration applies: start at lower doses and titrate based on weight (maximum 1.4 mg/kg/day or 100 mg/day, whichever is lower) 3
- Allow 6-12 weeks to assess full therapeutic effect of atomoxetine 3
Important caveat: If ADHD symptoms worsen or fail to improve adequately despite appropriate atomoxetine dosing, consider that valproic acid itself may be contributing to ADHD symptom exacerbation 2. In such cases, discuss with the prescribing neurologist or psychiatrist whether an alternative mood stabilizer or antiepileptic might be appropriate.
The combination is safe from a drug interaction standpoint, but requires clinical awareness of valproic acid's potential to independently affect ADHD symptomatology.